XRP and Dogecoin have emerged as early standouts in the first week of 2026, supported by fresh ETF inflows and a renewed risk-on tone across crypto markets.  DataXRP and Dogecoin have emerged as early standouts in the first week of 2026, supported by fresh ETF inflows and a renewed risk-on tone across crypto markets.  Data

US Spot XRP and Dogecoin ETFs Boom as Weekly Gains Surge Over 20%

2026/01/06 07:53
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

XRP and Dogecoin have emerged as early standouts in the first week of 2026, supported by fresh ETF inflows and a renewed risk-on tone across crypto markets. 

Data from SoSoValue shows XRP spot ETFs extended their inflow streak to 33 consecutive days, while Dogecoin spot ETFs recorded a sharp pickup in activity after weeks of muted flows.

XRP ETFs Remain in Green For 33 Days Since Launch

XRP spot ETFs posted a combined $13.59 million in net inflows on January 2, pushing total net assets to $1.37 billion. The sustained inflow streak stretches back to mid-November, when these funds were first launched. 

This shows persistent institutional demand for XRP even as broader crypto ETFs experienced intermittent outflows late last year.

XRP ETFs Inflow Streak Continues. Source: SoSoValue

Meanwhile, Dogecoin spot ETFs saw a notable shift. After days of flat activity, net inflows jumped by $2.3 million on January 2, lifting total DOGE ETF assets to $8.34 million. 

While the absolute figures remain small compared with XRP, the move marks a clear acceleration relative to December’s low-volume trading.

US Spot Dogecoin ETF Inflow. Source: SoSoValue

Price action has followed the same direction. XRP traded in a tight range earlier in the week before pushing toward the $2.30 level.

The move came after XRP reclaimed key short-term support zones around $2, easing sell pressure that defined late 2025.

Leveraged Dogecoin ETFs are Leading the US Markets

Dogecoin also extended its weekly rally. DOGE climbed from the low-$0.13 range to around $0.14, supported by broader memecoin strength and improving market sentiment. 

Technical momentum played a role, with short-term breakouts drawing traders back into high-beta assets.

Dogecoin Weekly Price Chart. Source: CoinGecko

Leverage has amplified those moves. According to ETF data highlighted by Bloomberg analyst Eric Balchunas, 2x leveraged Dogecoin ETFs ranked among the best-performing ETFs of early 2026, posting outsized gains within days. 

Taken together, the data points to two parallel trends. XRP continues to attract steady institutional capital through spot ETFs, tightening liquidity over time. 

Dogecoin, by contrast, is seeing shorter-term momentum flows, magnified by leverage and retail participation.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09